© 2004 by Oxford University Press
© 2004 Oxford University Press
ARTICLE |
Mesenchymal Stem Cells: Potential Precursors for Tumor Stroma and Targeted-Delivery Vehicles for Anticancer Agents
Affiliations of authors: Department of Blood and Marrow Transplantation, Section of Molecular Hematology and Therapy (MS, FCM, JLD CZ, MCH, REC, MA) and Department of Biostatistics and Applied Mathematics (BNB), The University of Texas M. D. Anderson Cancer Center, Houston, TX
Correspondence to: Michael Andreeff, MD, PhD, Department of Blood and Marrow Transplantation, The University of Texas M. D. Anderson Cancer Center, 1515 Holcombe Blvd., Unit 448, Houston, TX 77030 (e-mail: mandreef{at}mdanderson.org)
Background: High concentrations of interferon beta (IFN-
) inhibit malignant cell growth in vitro. However, the therapeutic utility of IFN- in vivo is limited by its excessive toxicity when administered systemically at high doses. Mesenchymal stem cells (MSC) can be used to target delivery of agents to tumor cells. We tested whether MSC can deliver IFN- to tumors, reducing toxicity. Methods: Human MSC were transduced with an adenoviral expression vector carrying the human IFN- gene (MSC-IFN- cells). Flow cytometry was used to measure tumor cell proliferation among in vitro co-cultures of MSC-IFN- cells and human MDA 231 breast carcinoma cells or A375SM melanoma cells. We used a severe combined immunodeficiency mouse xenograft model (4–10 mice per group) to examine the effects of injected MSC-IFN- cells and human recombinant IFN- on the growth of MDA 231- and A375SM-derived pulmonary metastases in vivo and on survival. All statistical tests were two-sided. Results: Co-culture of MSC-IFN- cells with A375SM cells or MDA 231 cells inhibited tumor cell growth as compared with growth of the tumor cells cultured alone (differences in mean percentage of control cell growth: –94.0% [95% confidence interval {CI} = –81.2% to –106.8%; P<.001] and –104.8% [95% CI = –82.1% to –127.5%; P<.001], respectively). Intravenous injection of MSC-IFN- cells into mice with established MDA 231 or A375SM pulmonary metastases led to incorporation of MSC in the tumor architecture and, compared with untreated control mice, to prolonged mouse survival (median survival for MDA 231–injected mice: 60 and 37 days for MSC-injected and control mice, respectively [difference = 23.0 days (95% CI = 14.5 to 34.0 days; P<.001]; median survival for A375SM-injected mice: 73.5 and 30.0 days for MSC-injected and control mice, respectively [difference = 43.5 days (95% CI = 37.0 to 57.5 days; P<.001]). By contrast, intravenous injection of recombinant IFN- did not prolong survival in the same models (median survival for MDA 231–injected mice: 41.0 and 37.0 days for IFN-–injected and control mice, respectively [difference = 4 days, 95% CI = –5 to 10 days; P = .308]; median survival for A375SM-injected mice: 32.0 and 30.0 days for IFN-–injected and control mice, respectively [difference = 2 days, 95% CI = 0 to 4.5 days; P = .059]). Conclusions: Injected MSC-IFN- cells suppressed the growth of pulmonary metastases, presumably through the local production of IFN- in the tumor microenvironment. MSC may be an effective platform for the targeted delivery of therapeutic proteins to cancer sites.
CiteULike 
Connotea 
Del.icio.us What's this?
Correspondence about this Article
- Re: Mesenchymal Stem Cells: Potential Precursors for Tumor Stroma and Targeted-Delivery Vehicles for Anticancer Agents
- Dominik Wolf, Holger Rumpold, Ruth Koeck, and Eberhard Gunsilius
J Natl Cancer Inst 2005 97: 540-541.[Extract] [Full Text] [PDF]
- RESPONSE: Re: Mesenchymal Stem Cells: Potential Precursors for Tumor Stroma and Targeted-Delivery Vehicles for Anticancer Agents
- Frank Marini, Matus Studeny, and Michael Andreeff
J Natl Cancer Inst 2005 97: 541-542.[Extract] [Full Text] [PDF]
This article has been cited by other articles:
|
|
 |
|
  Y. Lu, W. Yang, C. Qin, L. Zhang, J. Deng, S. Liu, and Z. Qin Responsiveness of Stromal Fibroblasts to IFN-{gamma} Blocks Tumor Growth via Angiostasis J. Immunol., November 15, 2009; 183(10): 6413 - 6421. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 G. V. Rosland, A. Svendsen, A. Torsvik, E. Sobala, E. McCormack, H. Immervoll, J. Mysliwietz, J.-C. Tonn, R. Goldbrunner, P. E. Lonning, et al. Long-term Cultures of Bone Marrow-Derived Human Mesenchymal Stem Cells Frequently Undergo Spontaneous Malignant Transformation Cancer Res., July 1, 2009; 69(13): 5331 - 5339. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
M. R. Loebinger, A. Eddaoudi, D. Davies, and S. M. Janes Mesenchymal Stem Cell Delivery of TRAIL Can Eliminate Metastatic Cancer Cancer Res., May 15, 2009; 69(10): 4134 - 4142. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 S. B. Coffelt, F. C. Marini, K. Watson, K. J. Zwezdaryk, J. L. Dembinski, H. L. LaMarca, S. L. Tomchuck, K. H. zu Bentrup, E. S. Danka, S. L. Henkle, et al. The pro-inflammatory peptide LL-37 promotes ovarian tumor progression through recruitment of multipotent mesenchymal stromal cells PNAS, March 10, 2009; 106(10): 3806 - 3811. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
C. Ganta, D. Chiyo, R. Ayuzawa, R. Rachakatla, M. Pyle, G. Andrews, M. Weiss, M. Tamura, and D. Troyer Rat Umbilical Cord Stem Cells Completely Abolish Rat Mammary Carcinomas with No Evidence of Metastasis or Recurrence 100 Days Post-Tumor Cell Inoculation Cancer Res., March 1, 2009; 69(5): 1815 - 1820. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
P. J. Mishra, P. J. Mishra, J. W. Glod, and D. Banerjee Mesenchymal Stem Cells: Flip Side of the Coin Cancer Res., February 15, 2009; 69(4): 1255 - 1258. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
A. W. Studebaker, G. Storci, J. L. Werbeck, P. Sansone, A. K. Sasser, S. Tavolari, T. Huang, M. W.Y. Chan, F. C. Marini, T. J. Rosol, et al. Fibroblasts Isolated from Common Sites of Breast Cancer Metastasis Enhance Cancer Cell Growth Rates and Invasiveness in an Interleukin-6-Dependent Manner Cancer Res., November 1, 2008; 68(21): 9087 - 9095. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 M. R. Loebinger, E. K. Sage, and S. M. Janes Mesenchymal Stem Cells as Vectors for Lung Disease Proceedings of the ATS, August 15, 2008; 5(6): 711 - 716. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
D. J. Weiss, J. K. Kolls, L. A. Ortiz, A. Panoskaltsis-Mortari, and D. J. Prockop Stem Cells and Cell Therapies in Lung Biology and Lung Diseases Proceedings of the ATS, July 15, 2008; 5(5): 637 - 667. [Full Text] [PDF]
|
|
|
|
|
|
N. Eliopoulos, M. Francois, M.-N. Boivin, D. Martineau, and J. Galipeau Neo-Organoid of Marrow Mesenchymal Stromal Cells Secreting Interleukin-12 for Breast Cancer Therapy Cancer Res., June 15, 2008; 68(12): 4810 - 4818. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
P. J. Mishra, P. J. Mishra, R. Humeniuk, D. J. Medina, G. Alexe, J. P. Mesirov, S. Ganesan, J. W. Glod, and D. Banerjee Carcinoma-Associated Fibroblast-Like Differentiation of Human Mesenchymal Stem Cells Cancer Res., June 1, 2008; 68(11): 4331 - 4339. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 S. Fortier, M. Touaibia, S. Lord-Dufour, J. Galipeau, R. Roy, and B. Annabi Tetra- and hexavalent mannosides inhibit the pro-apoptotic, antiproliferative and cell surface clustering effects of concanavalin-A: Impact on MT1-MMP functions in marrow-derived mesenchymal stromal cells Glycobiology, February 1, 2008; 18(2): 195 - 204. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
A. H. Klopp, E. L. Spaeth, J. L. Dembinski, W. A. Woodward, A. Munshi, R. E. Meyn, J. D. Cox, M. Andreeff, and F. C. Marini Tumor Irradiation Increases the Recruitment of Circulating Mesenchymal Stem Cells into the Tumor Microenvironment Cancer Res., December 15, 2007; 67(24): 11687 - 11695. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 A. K. Sasser, N. J. Sullivan, A. W. Studebaker, L. F. Hendey, A. E. Axel, and B. M. Hall Interleukin-6 is a potent growth factor for ER-{alpha}-positive human breast cancer FASEB J, November 1, 2007; 21(13): 3763 - 3770. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 R.M. Dwyer, S.M. Potter-Beirne, K.A. Harrington, A.J. Lowery, E. Hennessy, J.M. Murphy, F.P. Barry, T. O'Brien, and M.J. Kerin Monocyte Chemotactic Protein-1 Secreted by Primary Breast Tumors Stimulates Migration of Mesenchymal Stem Cells Clin. Cancer Res., September 1, 2007; 13(17): 5020 - 5027. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
L. Kucerova, V. Altanerova, M. Matuskova, S. Tyciakova, and C. Altaner Adipose Tissue-Derived Human Mesenchymal Stem Cells Mediated Prodrug Cancer Gene Therapy Cancer Res., July 1, 2007; 67(13): 6304 - 6313. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 C. Martinez, T. J. Hofmann, R. Marino, M. Dominici, and E. M. Horwitz Human bone marrow mesenchymal stromal cells express the neural ganglioside GD2: a novel surface marker for the identification of MSCs Blood, May 15, 2007; 109(10): 4245 - 4248. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 J.-C. Currie, S. Fortier, A. Sina, J. Galipeau, J. Cao, and B. Annabi MT1-MMP Down-regulates the Glucose 6-Phosphate Transporter Expression in Marrow Stromal Cells: A MOLECULAR LINK BETWEEN PRO-MMP-2 ACTIVATION, CHEMOTAXIS, AND CELL SURVIVAL J. Biol. Chem., March 16, 2007; 282(11): 8142 - 8149. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
P. B. Gupta, D. Proia, O. Cingoz, J. Weremowicz, S. P. Naber, R. A. Weinberg, and C. Kuperwasser Systemic Stromal Effects of Estrogen Promote the Growth of Estrogen Receptor-Negative Cancers Cancer Res., March 1, 2007; 67(5): 2062 - 2071. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
M. K. Danks, K. J. Yoon, R. A. Bush, J. S. Remack, M. Wierdl, L. Tsurkan, S. U. Kim, E. Garcia, M. Z. Metz, J. Najbauer, et al. Tumor-Targeted Enzyme/Prodrug Therapy Mediates Long-term Disease-Free Survival of Mice Bearing Disseminated Neuroblastoma Cancer Res., January 1, 2007; 67(1): 22 - 25. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 M. Andreeff, J. Dembinski, B. M. Hall, M. Studeny, X. Ling, M. Cabreira-Hansen, A. K. Sasser, T. McQueen, F. Lang, and F. C. Marini Mesenchymal Stem Cells Selectively Engraft into Tumor Stroma and Produce Potent Antitumor Proteins In Situ. Blood (ASH Annual Meeting Abstracts), November 16, 2006; 108(11): 352 - 352. [Abstract] [PDF]
|
|
|
|
|
|
Y. Ikehara, T. Niwa, L. Biao, S. K. Ikehara, N. Ohashi, T. Kobayashi, Y. Shimizu, N. Kojima, and H. Nakanishi A Carbohydrate Recognition-Based Drug Delivery and Controlled Release System using Intraperitoneal Macrophages as a Cellular Vehicle. Cancer Res., September 1, 2006; 66(17): 8740 - 8748. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 A. Y. Khakoo, S. Pati, S. A. Anderson, W. Reid, M. F. Elshal, I. I. Rovira, A. T. Nguyen, D. Malide, C. A. Combs, G. Hall, et al. Human mesenchymal stem cells exert potent antitumorigenic effects in a model of Kaposi's sarcoma J. Exp. Med., May 15, 2006; 203(5): 1235 - 1247. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
D. J. Weiss, M. A. Berberich, Z. Borok, D. B. Gail, J. K. Kolls, C. Penland, and D. J. Prockop Adult Stem Cells, Lung Biology, and Lung Disease Proceedings of the ATS, May 1, 2006; 3(3): 193 - 207. [Full Text] [PDF]
|
|
|
|
 |
|
 K. S. Aboody, J. Najbauer, N. O. Schmidt, W. Yang, J. K. Wu, Y. Zhuge, W. Przylecki, R. Carroll, P. M. Black, and G. Perides Targeting of melanoma brain metastases using engineered neural stem/progenitor cells Neuro-oncol, April 1, 2006; 8(2): 119 - 126. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 S. Komarova, Y. Kawakami, M. A. Stoff-Khalili, D. T. Curiel, and L. Pereboeva Mesenchymal progenitor cells as cellular vehicles for delivery of oncolytic adenoviruses. Mol. Cancer Ther., March 1, 2006; 5(3): 755 - 766. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
N. C. Direkze, R. Jeffery, K. Hodivala-Dilke, T. Hunt, R. J. Playford, G. Elia, R. Poulsom, N. A. Wright, and M. R. Alison Bone Marrow-Derived Stromal Cells Express Lineage-Related Messenger RNA Species Cancer Res., February 1, 2006; 66(3): 1265 - 1269. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 V Valiunas, Y. Y Polosina, H Miller, I. A Potapova, L Valiuniene, S Doronin, R. T Mathias, R. B Robinson, M. R Rosen, I. S Cohen, et al. Connexin-specific cell-to-cell transfer of short interfering RNA by gap junctions J. Physiol., October 15, 2005; 568(2): 459 - 468. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 D. Wolf, H. Rumpold, R. Koeck, and E. Gunsilius Re: Mesenchymal Stem Cells: Potential Precursors for Tumor Stroma and Targeted-Delivery Vehicles for Anticancer Agents J Natl Cancer Inst, April 6, 2005; 97(7): 540 - 541. [Full Text] [PDF]
|
|
|
|
|
|
F. Marini, M. Studeny, and M. Andreeff RESPONSE: Re: Mesenchymal Stem Cells: Potential Precursors for Tumor Stroma and Targeted-Delivery Vehicles for Anticancer Agents J Natl Cancer Inst, April 6, 2005; 97(7): 541 - 542. [Full Text] [PDF]
|
|